Himalaya Therapeutics is focused on developing innovative cancer therapies through its proprietary technology known as Conditionally Active Biologics (CAB). This platform enables the creation of antibodies that selectively target tumor cells while minimizing effects on normal cells, thereby enhancing safety and potency. The CAB antibodies are designed to respond to the unique characteristics of the tumor microenvironment (TME), which has a lower pH compared to healthy tissues. This allows the antibodies to bind effectively to tumor cells when in proximity, while remaining inactive in other areas of the body. The reversible nature of this binding mechanism ensures that the antibodies can switch "off" when not near a tumor, reducing off-target effects and widening the therapeutic window.

The CAB technology supports a robust pipeline of product candidates aimed at various validated tumor cell proteins. This versatility allows for the development of different therapeutic formats, including antibody-drug conjugates (ADCs) and bispecific antibodies. Himalaya's lead candidates target AXL and ROR2, with promising preclinical and early-phase clinical data indicating potential efficacy in challenging cancers such as sarcoma, melanoma, and non-small cell lung cancer (NSCLC). The ongoing global clinical trials have shown encouraging results, including complete responses in some patients, highlighting the potential of CAB technology to improve treatment outcomes for cancer patients.

China

Himalaya is a clinical stage, therapeutic company focused on developing innovative, differentiated therapies in greater china and worldwide. The company has exclusive rights to deploy CAB antibodies in its territories, with the goal of delivering safer, more potent cancer therapies to patients timely and cost effectively.

Himalaya Therapeutics

Company Details